Drug
Mirdametinib clinical trials
Also written PD-0325901.
- studies test it
- 26
- open now
- 15
- in phase 3
- 0
- first study started
- 2004
Keep track of what changes. Save the mirdametinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
24 studies that test it; most in 2026 (6); 2 more planned to start later
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2014 | 4 |
| 2019 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 16
- Phase 2
- 18
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 17
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (5) · National Cancer Institute (NCI) (3) · University of Alabama at Birmingham (2) · Memorial Sloan Kettering Cancer Center (2) · Pfizer (2) · BeiGene (1) · The Netherlands Cancer Institute (1) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Palbociclib (2) · Carbamazepine (1) · BGB-283 (1) · Dacomitinib (1) · Binimetinib (1) · Probenecid (1) · Vorinostat (1) · Alpelisib (1)
Studies
Open first, then newest update. How each study uses mirdametinib is read from its arms, and is right about nine times in ten.
Testing it · 26
- Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young AdultsNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07891286Written as Mirdametinib
- A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasNot yet recruitingPhase 1SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT07850635Written as Mirdametinib
- Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPKRecruitingPhase 1/2St. Justine's HospitalNCT06666348Written as Mirdametinib
- Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibRecruitingPhase 1SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT06997276Written as Mirdametinib (MEK Inhibitor)
- A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy ParticipantsRecruitingPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT07840612Written as Mirdametinib
- Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT07061951Written as Mirdametinib
- Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade GliomaNot yet recruitingPhase 2University of Alabama at BirminghamNCT07521657Written as mirdametinib with radiation
- Mirdametinib in Histiocytic DisordersRecruitingPhase 2Children's Hospital Medical Center, CincinnatiNCT06153173Written as Mirdametinib
- A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06843967Written as Mirdametinib
- SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade GliomaRecruitingPhase 1/2St. Jude Children's Research HospitalNCT04923126Written as Mirdametinib
- A Study of Mirdametinib in People With Central Nervous System TumorsRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07539441Written as Mirdametinib
- A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]RecruitingEarly Phase 1University of MinnesotaNCT06693284Written as mirdametinib and vorinostat
- A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular MalformationsRecruitingPhase 2Murdoch Childrens Research InstituteNCT05983159Written as Mirdametinib
- Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).RecruitingPhase 1/2Johns Hopkins UniversityNCT06159166Written as Mirdametinib
- Mirdametinib in Patients With Advanced NF1-mutant MelanomaRecruitingPhase 2Kevin Kim, MDNCT07237100Written as Mirdametinib
- Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple MyelomaSuspendedPhase 1/2National Cancer Institute (NCI)NCT06876142Written as Mirdametinib
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasActive, not recruitingPhase 2SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT03962543Written as Mirdametinib (PD-0325901) oral capsule or dispersible tablet
- Mirdametinib + BGB-3245 in Advanced Solid TumorsTerminatedPhase 1/2SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT05580770Written as Mirdametinib 2mg
- To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy ParticipantsCompletedPhase 1SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT07279233Written as Mirdametinib
- Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid TumorsCompletedPhase 1BeiGeneNCT03905148Written as mirdametinib
See all 26 studies that test mirdametinib →
Given in every arm · 2 — mirdametinib is usual care beside what is tested
- A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor CancerCompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT05054374Written as Mirdametinib
- Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced CancerTerminatedPhase 1PfizerNCT01347866Written as PD-0325901
Codes
What other systems call mirdametinib · ClinicalTrials.gg INT004850
- MeSH (NLM) C506614mirdametinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 86K0J5AK6MMIRDAMETINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27088255mirdametinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C52195MirdametinibOne source FDA
- DrugBank DB07101One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C506614 | mirdametinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 86K0J5AK6M | MIRDAMETINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088255 | mirdametinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C52195 | Mirdametinib | One source FDA |
| DrugBank | DB07101 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.